Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
Parisa Momtaz,1,2 Michael A Postow1,2 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical College, New York, NY, USA Abstract: T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immu...
Main Authors: | Momtaz P, Postow MA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-11-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Online Access: | http://www.dovepress.com/immunologic-checkpoints-in-cancer-therapy-focus-on-the-programmed-deat-peer-reviewed-article-PGPM |
Similar Items
-
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
by: Jingjing Fan, et al.
Published: (2020-10-01) -
Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
by: Shahla Bari, et al.
Published: (2019-01-01) -
Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01) -
Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
by: Shahla Bari, et al.
Published: (2019-01-01) -
Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
by: Takayuki Murata
Published: (2021-04-01)